J&J shines spot­light on can­cer spe­cial­ty pro­fes­sion in new aware­ness and sup­port ef­fort

Mul­ti­ple myelo­ma is a rare and com­plex blood can­cer and of­ten in­cludes ad­vanced prac­tice providers, or APPs, as part of the pa­tient care team. But even many myelo­ma pa­tients aren’t fa­mil­iar with the term, ac­cord­ing to a J&J Janssen On­col­o­gy sur­vey done in con­junc­tion with the Ad­vanced Prac­ti­tion­ers So­ci­ety for Hema­tol­ogy & On­col­o­gy (AP­SHO).

The US sur­vey found 36% of mul­ti­ple myelo­ma pa­tients weren’t aware of the term APP, which is typ­i­cal­ly a nurse prac­ti­tion­er or physi­cian as­sis­tant with spe­cial­ty train­ing, in this case for myelo­ma blood can­cers. Once they un­der­stood who APPs were though, 93% agreed they are es­sen­tial to pa­tient care. A ma­jor­i­ty (61%) al­so said they were more com­fort­able ask­ing their APPs ques­tions than ask­ing their doc­tors or on­col­o­gists.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER